Pleased to share our Trends in Cancer article on the U.S. FDA approval of lifileucel for melanoma.

🧬First cellular therapy approved for solid tumours
🧬Could in-house manufacture slash future TIL costs?

cell.com/trends/cancer/…

Dr Mark Lythgoe Andrew Furness The Royal Marsden NHS Foundation Trust

Updated outcomes from phase II Chinese study of lorlatinib 100mg qday in previously treated #ALK NSCLC Clinical Lung Cancer. PFS post crizotinib was 26.3m. PFS after other ALK TKIs was 5.6m. No new safety signals with longer 3y f/u.

clinical-lung-cancer.com/article/S1525-…

UCLH clinical oncologist @drhmshaw is leading an international clinical trial testing a novel cancer immunotherapy which may prevent skin cancer from recurring.

Find out more about the risk-reducing therapy: buff.ly/3Wh9ieF

for those who enjoyed the discussion on systemic therapy for operable early stage NSCLC by Mary O'Brien at #btog24 BTOG yesterday, here is a recent meta-analysis on the subject jamanetwork.com/journals/jaman…

Well done Thubeena Manickavasagar on a fab poster from Biomedical Engineering & Imaging Sciences BTOG

discussing validation of radiomics models determining CT parameters predictive of PD-L1 #NSCLC

Some of the amazing work with collaborations between Biomedical Engineering & Imaging Sciences and Guy's and St Thomas' cancer 💪🏻

#BTOG24
Vicky Goh

🎥We had the pleasure of catching up with Dr Adam Januszewski this morning to discuss the BTOG Therapeutics Symposium, ADCs in #lungcancer , and more at #BTOG24

👀Interview coming soon to VJOncology.com

BTOG #LCSM #NSCLC #SCLC #LungCancer

Content I'm here for 🍿 BTOG #BTOG24

The maestro Eric Lim presenting a blistering rebuttal to critique of #MARS2

Systematic, scientific, rational. Fantastic performance 👏🏾

Mariana Brandao: What defines operable NSCLC?

EORTC consensus guidelines:
🔸 T3N1 = ✅ (resectable)
🔸T3 single station N2 = ✅
🔸T3 multi-station N2 = ❌
🔸T3 Bulky N2 = most ❌
🔸T4 N0/1 = ✅, unless infiltration of major structures

#LCSM #BTOG24

Great work from Dr Elghady looking at adjuvant osimertinib in resected EGFR (ADAURA); RWE showing higher rates of dose reduction and cessation compared to the trial. This reflects my personal clinical experience. #BTOG24 #LCSM

Come meet our wonderful UCLH UCL Cancer Institute trainee Tom at poster 102 BTOG - he’s got tea and cake!

He presents his work on HIV + HBV testing pre-SACT in lung cancer

Demonstrating education can improve testing!

More work needed to meet UK SACT board HBV guidelines

#BTOG24

This recent study in BMJ Oncology found that there may be confounding in the overall survival estimates of phase III oncology trials because of differences in post-progression therapies. bmjoncology.bmj.com/content/3/1/e0…

Ethan Ludmir MD Alexander Sherry and colleagues

Frimley Health NHS Foundation Trust 💙 Surrey and Sussex Cancer Alliance BTOG HASAG Asbestos Disease Support so glad to be able to present our poster at BTOG to showcase the amazing work we have done with the targeted lung health checks Frimley Health NHS Foundation Trust 💙

Real world 🇬🇧 Lorlatinib study

🔹 2L mPFS = 5.0m
🔹 3L+ mPFS = 17.2m
🔹 3% developed CNS on treatment

Limited activity in 2L sobering. Perhaps 1L Lorlatinib, given CROWN data, becoming a more attractive option 🤔

Great work from Tylan Lucas & Daniel Hughes

#LCSM #BTOG24

Egbert Smit: Will ADCs really impact on NSCLC care?

Interesting facts:
🤔 99% of payload does not reach tumour
🤔 ADCs do not increase MTD vs chemo
🤔 But ORR double compared to chemo

👉 Suggests ADCs are immunotherapy as much as chemo delivery system

#BTOG24 #LCSM

Dr Corrie discusses the NIHR Research strategy to delivering #CancerVaccines , highlighting UK partnership-collaboration with Moderna & BioNTech SE & the UK Vaccine Innovation Pathway Programme; national sequencing effort for personalised cancer vaccines #BTOG24 BTOG

.Fiona Blackhall discusses DLL3 targeting in SCLC. CRS around 50% any grade rate tox across all agents. Incidence reduces by cycle. Many trials in development. Can healthcare systems deliver? Answer is Yes! And optimism for positive trials. #BTOG24

Congrats to all successful new MedOnc trainees. Excellent dedicated empathetic people joining is wonderful to see. Join Association of Cancer Physicians for peer support mentoring & great education. #cancercare #research #innovation

#ELCC24

Proud of our own ⁦Gerard Walls⁩ 🇮🇪presenting long term outcomes from the trial CONVERT, evaluating once v twice daily RT in SCLC, showing less tox for twice daily, but no OS diff btwn arms

#ESMOambassadors ⁦ESMO - Eur. Oncology⁩ ⁦The Christie Charity⁩ ⁦ICAT Programme⁩